L-glutamic acid γ-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide | 512783-91-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-glutamic acid γ-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide
• 英文别名: L-glutamic acid γ-tert-butyl ester α-(3-trifluoromethyl)benzylamide；L-glutamic acid γ-t-butyl ester α-(3-trifluoromethyl)benzylamide
• CAS: 512783-91-4
• 化学式: C₁₇H₂₃F₃N₂O₃
• 分子量: 360.376
• InChiKey: KSVPUYZLPCZDSK-ZDUSSCGKSA-N

物化性质

• 沸点：
  482.7±45.0 °C(Predicted)
• 密度：
  1.195±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.77
• 重原子数：
  25.0
• 可旋转键数：
  6.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  81.42
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  L-glutamic acid γ-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide 在 甲酸 、 N-羟基-7-氮杂苯并三氮唑 、 magnesium sulfate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (S)-N-(3-(trifluoromethyl)benzyl)-5-oxo-2-((3S,4R)-2-oxo-3-((S)-2-oxo-4-phenyloxazolidin-3-yl)-4-((E)-styryl)azetidin-1-yl)-5-(4-(piperidin-1-ylmethyl)piperidin-1-yl)pentanamide
  参考文献：
  名称：

  Azetidinones as vasopressin V1a antagonists

  摘要：

  The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing hormone receptor. Structure-activity relationships for the series were explored to optimize receptor affinity and pharmacokinetic properties, resulting in compounds with K-i values < 1 nM and brain levels after oral dosing similar to 100-fold higher than receptor affinities.[GRAPHICS](c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.12.031
• 作为产物：
  描述：

  (4S)-5-[(2,5-二氧代-1-吡咯烷基)氧基]-5-氧代-4-[[(苯基甲氧基)羰基]氨基]戊酸叔丁酯 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 L-glutamic acid γ-tert-butyl ester α-[3-(trifluoromethyl)benzyl]amide
  参考文献：
  名称：

  Azetidinones as vasopressin V1a antagonists

  摘要：

  The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing hormone receptor. Structure-activity relationships for the series were explored to optimize receptor affinity and pharmacokinetic properties, resulting in compounds with K-i values < 1 nM and brain levels after oral dosing similar to 100-fold higher than receptor affinities.[GRAPHICS](c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.12.031